Additional Relevant Details Bristol-Myers Squibb received two positive CHMP opinions for Opdivo (nivolumab) for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy, and adults with advanced renal cell carcinoma (RCC) after prior therapy.  Both indications are supported by Phase 3 studies in which Opdivo demonstrated a survival benefit versus a standard of care.  The EC now reviews Opdivo for approval of these new indications